Your browser doesn't support javascript.
loading
Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy.
Alves, Christiano R R; Ha, Leillani L; Yaworski, Rebecca; Sutton, Emma R; Lazzarotto, Cicera R; Christie, Kathleen A; Reilly, Aoife; Beauvais, Ariane; Doll, Roman M; de la Cruz, Demitri; Maguire, Casey A; Swoboda, Kathryn J; Tsai, Shengdar Q; Kothary, Rashmi; Kleinstiver, Benjamin P.
Affiliation
  • Alves CRR; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. calves2@mgh.harvard.edu.
  • Ha LL; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. calves2@mgh.harvard.edu.
  • Yaworski R; Department of Neurology, Harvard Medical School, Boston, MA, USA. calves2@mgh.harvard.edu.
  • Sutton ER; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Lazzarotto CR; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Christie KA; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Reilly A; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Beauvais A; Centre for Neuromuscular Disease, University of Ottawa, Ottawa, Ontario, Canada.
  • Doll RM; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • de la Cruz D; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Maguire CA; Centre for Neuromuscular Disease, University of Ottawa, Ottawa, Ontario, Canada.
  • Swoboda KJ; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Tsai SQ; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Kothary R; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Kleinstiver BP; Department of Pathology, Harvard Medical School, Boston, MA, USA.
Nat Biomed Eng ; 8(2): 118-131, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38057426
ABSTRACT
Spinal muscular atrophy (SMA) is caused by mutations in SMN1. SMN2 is a paralogous gene with a C•G-to-T•A transition in exon 7, which causes this exon to be skipped in most SMN2 transcripts, and results in low levels of the protein survival motor neuron (SMN). Here we show, in fibroblasts derived from patients with SMA and in a mouse model of SMA that, irrespective of the mutations in SMN1, adenosine base editors can be optimized to target the SMN2 exon-7 mutation or nearby regulatory elements to restore the normal expression of SMN. After optimizing and testing more than 100 guide RNAs and base editors, and leveraging Cas9 variants with high editing fidelity that are tolerant of different protospacer-adjacent motifs, we achieved the reversion of the exon-7 mutation via an A•T-to-G•C edit in up to 99% of fibroblasts, with concomitant increases in the levels of the SMN2 exon-7 transcript and of SMN. Targeting the SMN2 exon-7 mutation via base editing or other CRISPR-based methods may provide long-lasting outcomes to patients with SMA.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Muscular Atrophy, Spinal / RNA-Binding Proteins Limits: Animals / Humans Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Muscular Atrophy, Spinal / RNA-Binding Proteins Limits: Animals / Humans Language: En Year: 2024 Type: Article